This version of the guidance has been updated to reflect several important developments, including the recent approvals of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. Updated recommendations reflecting these approvals are provided throughout the guidance.
In addition to updates to all the sections, the following new sections have been added to the guidance:
Conducted at the request of the Department of Health and Human Services’ Office of Infectious Disease and HIV/AIDS Policy (OIDP), this report identifies the barriers to greater integration of OUD and infectious disease services and Read more…
On September 10, 2019, the Centers for Disease Control and Prevention (CDC) released their 2017 Viral Hepatitis Surveillance Report. The report comes after the World Health Assembly in 2016, where the United States agreed to Read more…
The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence review on screening for hepatitis C virus infection in adolescents and adults. The Draft Recommendation Statement and Draft Evidence Read more…